HONG KONG, Oct. 22, 2014 /PRNewswire/ — Golden Meditech Holdings Limited (the "Company" or "Golden Meditech", 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, announced that it has brought in Gem Power International Limited as a strategic investor through issuing the convertible notes of an aggregate principal amount of US$20 million (equivalent to approximately HK$155 million). Gem Power International Limited is an indirect wholly-owned subsidiary of CCB International (Holdings) Limited ("CCBI").
The convertible notes carry a 5% interest per annum and the convertible notes holder can convert the convertible notes into ordinary shares of the Company at an initial conversion price of HK$1.40 (subject to adjustments). Upon full conversion of the principal amount of the convertible notes, the total ordinary shares issuable represents approximately 6.05% of the enlarged share capital of the Company.
Mr. KAM Yuen, Chairman and Chief Executive Officer said, "We are pleased to see CCBI shares the same vision as we do with mainland China’s growing healthcare industry. With the demand for high quality healthcare services and medical devices flourishing, Golden Meditech believes bringing in strategic investor will pave the way for the Company to better capture the opportunities amidst mainland China’s ongoing healthcare reform."
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited (www.goldenmeditech.com) is China’s leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, including cord blood stem cells storage and hospital management, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.